Jefferies Group’s Denali Therapeutics DNLI Stock Holding History

Jefferies Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-60,000	Closed	-$5.03M	–	1706
2020 Q4	$5.03M	Buy	+60,000	New	+$3.63M	0.04%	408

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jefferies Group's DNLI Position: Q2 2021 in Review

Jefferies Group sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 21,100 shares — an estimated $1.2M sold.

Jefferies Group first reported a position in DNLI in Q3 2019 and held it in 3 quarters. The position peaked at $2.51M in Q4 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

Jefferies Group reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 21,100 Denali Therapeutics shares in Q2 2021, an estimated $1.2M.
Jefferies Group first reported a position in Denali Therapeutics in Q3 2019 and held it in 3 quarters.
Jefferies Group's Denali Therapeutics position peaked at $2.51M in Q4 2020.
210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.